Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00096278 · ClinicalTrials.gov registry record · Phase 3
Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer
A Phase 3 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 3
- Development phase
- 2,710
- Enrollment target
NCT00096278: Completed Phase 3 study, sponsored by National Cancer Institute (NCI).
NCT00096278 is a Phase 3 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 2,710 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00096278, a Phase 3 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,710 participants
- Enrollment target
Study Summary
This randomized phase III trial is studying giving oxaliplatin, leucovorin, and fluorouracil together with bevacizumab to see how well it works compared to oxaliplatin, leucovorin, and fluorouracil alone in treating patients who have undergone surgery for stage II or stage III colon cancer. Drugs used in chemotherapy, such as oxaliplatin, leucovorin, and fluorouracil, work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as bevacizumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Bevacizumab may also stop the growth of tumor cells by stopping blood flow to the tumor. Giving chemotherapy together with bevacizumab may kill more tumor cells. It is not yet known whether treatment with oxaliplatin, leucovorin, and fluorouracil is more effective with or without bevacizumab in treating patients who have undergone surgery for colon cancer.
Interventions
- DRUG Fluorouracil
- DRUG Oxaliplatin
- BIOLOGICAL Bevacizumab
- DRUG Leucovorin Calcium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,710 participants |
| Start Date | 2004-09-15 |
| Est. Completion | 2012-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00096278
The ClinicalTrials.gov registry entry for NCT00096278 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,710 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Fluorouracil is the first listed.
NCT00096278 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00096278 about?
NCT00096278 is a clinical study titled "Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer". This randomized phase III trial is studying giving oxaliplatin, leucovorin, and fluorouracil together with bevacizumab to see how well it works compared to oxaliplatin, leucovorin, and fluorouracil alone in treating patients who have undergone surgery for stage II or stage III colon cancer. Drugs us...
What is the current status of trial NCT00096278?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,710 participants. The study started on 2004-09-15. Estimated completion is 2012-12-31.
What interventions are being tested in trial NCT00096278?
The interventions under investigation include: Fluorouracil (DRUG), Oxaliplatin (DRUG), Bevacizumab (BIOLOGICAL), Leucovorin Calcium (DRUG).
Who is sponsoring clinical trial NCT00096278?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.